Nicholas Piramal to focus on mega brands
18 Jun 2002
Nicholas Piramal’s primary brands — Phensedyl, Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint — account for 67 per cent of the company’s turnover, whereas its secondary brands — Paraxin, Flagyl and Omnatax — account for 24 per cent of its turnover. The secondary brands are the company’s cash cows.
The company plans to gradually phase out its tertiary brands that account for 9 per cent of its turnover.
The company will aggressively launch new products belonging to the high-growth therapeutic segments, which include oral anti-diabetics, anti-depressants, cardiovascular and anti-arthritic drugs. In the previous fiscal, drugs in the respiratory, cardiac, NSAIDs and psychiatry segment accounted for 42 per cent of the company’s formulation turnover.
As a consequence of its integration with Rhone-Poulenc India Ltd, the company has significantly reduced operational complexity of its plants. It has consolidated in-house manufacturing locations in order to align capacities with future demand requirements.